MIRM,ACAD,PCRX Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: VRTX GILD AKRO ENTA MDGL PTCT NBIX VKTX DVAX GLMD

| Held by: IWM VTI XBI IWO VXF IBB SCHA VTWO VHT FYC

Index	RUT	P/E	-	EPS (ttm)	-1.21	Insider Own	19.10%	Shs Outstand	50.06M	Perf Week	-2.30%
Market Cap	3.73B	Forward P/E	604.15	EPS next Y	0.12	Insider Trans	-2.28%	Shs Float	40.64M	Perf Month	14.08%
Enterprise Value	3.75B	PEG	-	EPS next Q	-0.16	Inst Own	94.18%	Short Float	16.88%	Perf Quarter	51.59%
Income	-58.56M	P/S	8.70	EPS this Y	66.86%	Inst Trans	3.23%	Short Ratio	11.27	Perf Half Y	66.76%
Sales	429.16M	P/B	14.58	EPS next Y	120.07%	ROA	-8.45%	Short Interest	6.86M	Perf YTD	79.71%
Book/sh	5.10	P/C	12.26	EPS next 5Y	-	ROE	-24.19%	52W High	78.10 -4.85%	Perf Year	77.90%
Cash/sh	6.06	P/FCF	432.58	EPS past 3/5Y	12.58% 4.14%	ROIC	-10.24%	52W Low	36.86 101.61%	Perf 3Y	192.44%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	160.13% -	Gross Margin	78.93%	Volatility	3.82% 3.64%	Perf 5Y	247.08%
Dividend TTM	-	EV/Sales	8.73	EPS Y/Y TTM	48.34%	Oper. Margin	-13.30%	ATR (14)	2.61	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.97	Sales Y/Y TTM	62.33%	Profit Margin	-13.65%	RSI (14)	63.07	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	3.13	EPS Q/Q	77.40%	SMA20	2.03%	Beta	0.83	Target Price	79.60
Payout	-	Debt/Eq	1.25	Sales Q/Q	64.09%	SMA50	20.40%	Rel Volume	0.55	Prev Close	75.99
Employees	322	LT Debt/Eq	1.24	Earnings	Aug 06 AMC	SMA200	50.13%	Avg Volume	608.72K	Price	74.31
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	63.22% 18.20%	Trades		Volume	336,373	Change	-2.21%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Citigroup	Buy	$21

Show Previous Ratings

Sep-10-25 06:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-25 08:00AM	Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study (Business Wire)
Aug-27-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-25 05:31PM	IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies \| DelveInsight (PR Newswire) +9.84%
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
11:20AM	Loading…
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) +12.04%
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-10-25 06:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-24-25 12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-17-25 12:36PM	Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up (Investor's Business Daily)
01:57PM	Loading…
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
Jun-10-25 08:40PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-25 11:31AM	Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? (Zacks)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
May-19-25 08:30AM	Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer (Business Wire)
May-14-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Data from Mirums VANTAGE PBC Study Showcased at EASL (Business Wire)
May-08-25 12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks) +9.75%
07:08AM	Q1 2025 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:29AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-07-25 09:17PM	Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth (Seeking Alpha)
09:17PM	Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-06-25 05:05PM	Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.13%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-04-25 06:45PM	Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities (Seeking Alpha)
Apr-30-25 08:30AM	Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (Business Wire)
Apr-28-25 08:30AM	Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses (Business Wire)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-14-25 08:30AM	Mirums LIVMARLI Now FDA Approved in Tablet Formulation (Business Wire)
Apr-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.67%
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
Mar-28-25 11:30AM	Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-27-25 08:30AM	LIVMARLI Now Approved in Japan for ALGS and PFIC (Business Wire)
Mar-24-25 05:17PM	Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (SeekingAlpha)
12:24PM	Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (SeekingAlpha)
Mar-21-25 12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
Mar-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 10:56AM	Q4 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.02%
02:22AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Feb-26-25 05:15PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update (Business Wire)
11:48AM	Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
09:55AM	Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know (Zacks)
Feb-24-25 08:30AM	Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) (Business Wire)
07:31AM	Mirum drug for rare genetic disease gains FDA approval (BioPharma Dive)
Feb-19-25 04:04PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 (Business Wire)
Feb-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-24-25 12:00PM	Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-14-25 08:50AM	Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-13-25 08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates (Business Wire) +6.49%
Jan-10-25 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-06-25 04:04PM	Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 11:30AM	Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? (Zacks)
Dec-10-24 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-06-24 06:46AM	Mirum Pharmaceuticals price target raised to $74 from $69 at JMP Securities (TipRanks)
Nov-14-24 08:00AM	Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire) +5.33%
Nov-13-24 02:09AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Nov-12-24 09:15AM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-08-24 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-24 04:30PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-04-24 04:30PM	Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 (Business Wire)
Oct-31-24 10:02AM	Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know (Zacks)
08:30AM	Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting (Business Wire)
Oct-23-24 08:49AM	Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth (Insider Monkey)
Oct-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis (Business Wire)
Oct-09-24 05:18PM	Mirum Pharmaceuticals Inc (MIRM) Q2 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Sep-10-24 08:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
11:31AM	Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-19-24 11:06AM	Mirum (MIRM) Banks on Livmarli, Overdependence a Concern (Zacks)
Aug-09-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.79%
Aug-08-24 11:01AM	Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top (Zacks)
Aug-07-24 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-31-24 04:30PM	Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024 (Business Wire)
Jul-29-24 07:28AM	Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains? (Zacks)
Jul-25-24 08:30AM	Mirums LIVMARLI Now Approved for PFIC in Patients 12 Months and Older (Business Wire)
Jul-12-24 01:22PM	Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves (Investor's Business Daily)
Jul-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-24 10:37AM	Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion (Zacks)
Jul-08-24 11:38AM	Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why (Zacks)
08:30AM	Mirum Pharmaceuticals LIVMARLI Approved in the European Union for Patients with PFIC (Business Wire)
Jun-28-24 02:26PM	MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50 (Investor's Business Daily)
08:30AM	Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX (Business Wire)
Jun-25-24 11:31AM	Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling (Investor's Business Daily)
Jun-18-24 11:14AM	Mirum (MIRM) Soars on Interim Data From Liver Disease Studies (Zacks) -11.36%
05:46AM	Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-17-24 08:00AM	Mirums Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies (Business Wire) +27.31%

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brege Laura	Director	Sep 11 '25	Option Exercise	15.00	17,000	255,000	32,703	Sep 12 08:00 PM
Brege Laura	Director	Sep 11 '25	Sale	74.40	17,000	1,264,868	15,703	Sep 12 08:00 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 12 '25	Sale	76.01	9,578	728,024	39,945	Sep 12 08:00 PM
LAURA BREGE	Director	Sep 11 '25	Proposed Sale	74.41	17,000	1,264,917		Sep 11 04:04 PM
Ramasastry Saira	Director	Sep 08 '25	Option Exercise	23.51	17,000	399,670	17,000	Sep 10 05:50 PM
SAIRA RAMASASTRY	Director	Sep 08 '25	Proposed Sale	77.04	17,000	1,309,716		Sep 08 04:06 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 12 '25	Option Exercise	26.49	2,954	78,251	31,190	Aug 12 08:00 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 12 07:57 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Sale	62.00	40,000	2,480,000	138,641	Aug 12 07:57 PM
CHRISTOPHER PEETZ	Officer	Aug 11 '25	Proposed Sale	62.00	40,000	2,480,000		Aug 11 04:06 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Option Exercise	6.27	10,000	62,700	12,426	Aug 08 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Sale	58.00	10,000	580,000	2,426	Aug 08 04:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 08 04:49 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Sale	55.25	40,000	2,210,040	138,641	Aug 08 04:49 PM
JOLANDA MARIE HOWE	Officer	Aug 07 '25	Proposed Sale	58.00	10,000	580,000		Aug 07 04:26 PM
CHRISTOPHER PEETZ	Officer	Aug 07 '25	Proposed Sale	55.25	40,000	2,210,040		Aug 07 04:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '25	Sale	48.25	564	27,213	2,903	Jul 03 06:48 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 03 '25	Sale	49.08	477	23,411	2,426	Jul 03 06:48 PM
JOLANDA MARIE HOWE	Officer	Jul 03 '25	Proposed Sale	49.08	477	23,411		Jul 03 01:13 PM
Fairey William	Director	Jun 11 '25	Sale	48.42	3,203	155,091	2,500	Jun 13 04:18 PM
WILLIAM C FAIREY	Director	Jun 11 '25	Proposed Sale	48.42	3,203	155,091		Jun 11 04:05 PM
Ramasastry Saira	Director	Jun 03 '25	Option Exercise	14.12	2,500	35,300	2,500	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 02 '25	Sale	46.20	5,703	263,492	0	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 03 '25	Sale	45.74	2,500	114,352	0	Jun 04 04:11 PM
SAIRA RAMASASTRY	Director	Jun 03 '25	Proposed Sale	45.74	2,500	114,352		Jun 03 05:07 PM
SAIRA RAMASASTRY	Director	Jun 02 '25	Proposed Sale	46.20	5,703	263,492		Jun 02 06:43 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 18 '25	Sale	44.45	2,415	107,343	2,426	Mar 19 05:40 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Option Exercise	2.94	52,900	155,526	59,547	Mar 18 09:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Sale	44.35	57,606	2,554,763	4,841	Mar 18 09:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 17 '25	Sale	44.21	7,879	348,364	18,672	Mar 18 09:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 17 '25	Sale	44.21	27,279	1,206,122	138,641	Mar 18 09:30 PM
Heron Patrick J	Director	Mar 14 '25	Buy	44.11	528	23,291	168,651	Mar 18 05:04 PM
Heron Patrick J	Director	Mar 17 '25	Buy	43.93	21	923	168,672	Mar 18 05:04 PM
JOLANDA MARIE HOWE	Officer	Mar 18 '25	Proposed Sale	44.45	2,415	107,343		Mar 18 04:12 PM
JOLANDA MARIE HOWE	Officer	Mar 17 '25	Proposed Sale	44.36	54,706	2,426,540		Mar 17 04:21 PM
Heron Patrick J	Director	Mar 10 '25	Buy	42.97	1,335	57,363	167,160	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 11 '25	Buy	43.77	963	42,155	168,123	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 06 '25	Buy	43.89	1,335	58,597	165,245	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 07 '25	Buy	43.21	580	25,064	165,825	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 04 '25	Buy	45.57	1,335	60,830	163,643	Mar 06 05:30 PM
Heron Patrick J	Director	Mar 05 '25	Buy	44.55	267	11,894	163,910	Mar 06 05:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 04 '25	Sale	45.58	14,850	676,928	12,111	Mar 05 04:28 PM
Radovich Peter	Officer	Mar 04 '25	Proposed Sale	45.52	14,850	675,956		Mar 04 04:43 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Option Exercise	2.94	40,000	117,440	155,920	Mar 04 04:26 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Sale	46.91	40,000	1,876,353	115,920	Mar 04 04:26 PM
CHRISTOPHER PEETZ	Officer	Mar 03 '25	Proposed Sale	46.91	40,000	1,876,280		Mar 03 04:49 PM
Radovich Peter	PRESIDENT AND COO	Feb 03 '25	Sale	48.22	2,627	126,681	26,961	Feb 04 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 03 '25	Sale	48.22	9,102	438,921	115,920	Feb 04 05:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 03 '25	Sale	48.22	1,064	51,309	4,232	Feb 04 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 24 '25	Sale	47.92	3,177	152,256	29,588	Jan 27 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 24 '25	Sale	47.92	902	43,228	3,524	Jan 27 04:48 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 24 '25	Sale	47.92	6,837	327,658	125,022	Jan 27 04:48 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 17 '25	Sale	45.86	6,969	319,598	5,649	Jan 21 04:21 PM
Radovich Peter	PRESIDENT AND COO	Jan 07 '25	Sale	42.82	1,998	85,545	27,015	Jan 08 04:44 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	42.82	7,489	320,644	119,359	Jan 08 04:42 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 07 '25	Sale	42.82	750	32,111	2,926	Jan 08 04:38 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Nov 14 '24	Option Exercise	2.94	2,500	7,350	4,926	Nov 15 05:34 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Nov 14 '24	Sale	47.10	2,500	117,752	2,426	Nov 15 05:34 PM
Heron Patrick J	Director	Sep 18 '24	Buy	37.40	115	4,301	162,308	Sep 20 04:39 PM

ACAD Acadia Pharmaceuticals Inc daily Stock Chart

Peers: NBIX BIIB VRTX INCY BMRN ALNY IONS REGN GILD AMGN

| Held by: IJR VTI IWM VB VBK FBT XBI VXF SPSM IWO

Index	RUT	P/E	17.74	EPS (ttm)	1.33	Insider Own	0.78%	Shs Outstand	168.61M	Perf Week	-6.53%
Market Cap	3.98B	Forward P/E	29.32	EPS next Y	0.81	Insider Trans	-4.14%	Shs Float	167.39M	Perf Month	-6.05%
Enterprise Value	3.28B	PEG	10.44	EPS next Q	0.14	Inst Own	101.33%	Short Float	5.54%	Perf Quarter	8.60%
Income	222.16M	P/S	3.91	EPS this Y	-60.90%	Inst Trans	-2.48%	Short Ratio	4.82	Perf Half Y	40.70%
Sales	1.02B	P/B	4.84	EPS next Y	51.41%	ROA	20.77%	Short Interest	9.28M	Perf YTD	28.66%
Book/sh	4.88	P/C	5.23	EPS next 5Y	1.70%	ROE	33.18%	52W High	26.65 -11.41%	Perf Year	51.06%
Cash/sh	4.52	P/FCF	21.29	EPS past 3/5Y	- -	ROIC	25.62%	52W Low	13.40 76.19%	Perf 3Y	40.12%
Dividend Est.	-	EV/EBITDA	31.52	Sales past 3/5Y	25.54% 23.08%	Gross Margin	91.97%	Volatility	3.80% 2.84%	Perf 5Y	-38.50%
Dividend TTM	-	EV/Sales	3.22	EPS Y/Y TTM	627.78%	Oper. Margin	8.86%	ATR (14)	0.77	Perf 10Y	-34.25%
Dividend Ex-Date	-	Quick Ratio	2.83	Sales Y/Y TTM	14.41%	Profit Margin	21.80%	RSI (14)	39.79	Recom	1.85
Dividend Gr. 3/5Y	- -	Current Ratio	2.91	EPS Q/Q	-21.30%	SMA20	-6.43%	Beta	0.78	Target Price	30.32
Payout	0.00%	Debt/Eq	0.07	Sales Q/Q	9.34%	SMA50	-1.18%	Rel Volume	0.80	Prev Close	24.20
Employees	654	LT Debt/Eq	0.05	Earnings	Aug 06 AMC	SMA200	20.33%	Avg Volume	1.93M	Price	23.61
IPO	May 27, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.86% 0.97%	Trades		Volume	1,539,800	Change	-2.44%

Date	Action	Analyst	Rating Change	Price Target Change
May-21-25	Upgrade	Deutsche Bank	Hold → Buy	$35
Feb-11-25	Initiated	Deutsche Bank	Hold	$22
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral	$23 → $20
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $20
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$31
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12
Nov-01-22	Initiated	Loop Capital	Hold	$17

Show Previous Ratings

Sep-12-25 04:05PM	Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology (Business Wire)
Sep-11-25 11:13AM	ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome (Insider Monkey)
Sep-08-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
04:53AM	ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial (Insider Monkey)
04:05PM	Loading…
Aug-26-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-25-25 04:05PM	Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer (Business Wire)
Aug-21-25 09:49AM	JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug (Zacks)
Aug-11-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-07-25 10:04AM	Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
Aug-06-25 05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:19PM	Acadia: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview (Business Wire)
Aug-05-25 06:00PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
09:32AM	Loading…
09:32AM	Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? (Zacks)
Aug-04-25 04:05PM	Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer (Business Wire)
12:23PM	Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? (Zacks)
11:07AM	Sarepta to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Aug-01-25 11:40AM	GMAB vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Jul-30-25 10:00AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-23-25 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 (Business Wire)
Jul-10-25 08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-04-25 11:40AM	KMDA or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Jul-03-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-26-25 08:23AM	Acadias very bullish sales forecast restores some confidence on Wall Street (BioPharma Dive)
Jun-25-25 08:00AM	Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers (Business Wire)
Jun-24-25 01:05PM	Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital (TipRanks)
Jun-18-25 11:40AM	KMDA vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Jun-17-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:40PM	Loading…
Jun-11-25 07:40PM	US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication (Insider Monkey)
Jun-09-25 04:01PM	U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID (pimavanserin) Composition of Matter Patent (Business Wire)
Jun-06-25 11:31AM	Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report? (Zacks)
Jun-05-25 09:05AM	Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 (Business Wire)
May-29-25 04:05PM	Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
May-27-25 04:05PM	Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise (Business Wire)
May-20-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:52PM	Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday (Insider Monkey)
10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-19-25 03:07PM	ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93 (Investor's Business Daily)
11:40AM	GSK or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks)
May-17-25 01:36PM	Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer (TipRanks)
01:36PM	Acadia Nuplazid patent ruling removes key overhang, says BMO Capital (TipRanks)
May-16-25 01:43PM	Delaware District Court Rules in Favor of Acadia in NUPLAZID (pimavanserin) Formulation Patent Litigation (Business Wire) +26.48%
May-09-25 06:26PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) (Zacks)
May-08-25 10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks) +14.31%
08:03AM	Q1 2025 ACADIA Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:28AM	ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-07-25 08:10PM	Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data (Seeking Alpha)
08:10PM	ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript (Seeking Alpha)
05:35PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Zacks)
04:30PM	Acadia: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview (Business Wire)
10:00AM	Here are the major earnings after the close today (Seeking Alpha)
May-05-25 04:05PM	Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference (Business Wire)
11:12AM	DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock? (Zacks)
10:00AM	Analysts Estimate Fortrea Holdings Inc. (FTRE) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
Apr-30-25 10:01AM	Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline (Zacks)
Apr-23-25 04:05PM	Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025 (Business Wire)
Apr-15-25 10:20AM	Buy The Dips, Sell The Rips (Seeking Alpha)
Apr-11-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-10-25 02:37PM	'Carp Special': $100,000 In A 52-Week Low-Quality Portfolio (Seeking Alpha) -5.68%
09:31AM	Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar? (Zacks)
Mar-28-25 11:30AM	Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? (Zacks)
Mar-27-25 02:50PM	Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SeekingAlpha)
08:46AM	SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug (Zacks)
Mar-25-25 05:40PM	Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha)
Mar-17-25 03:39PM	Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? (Insider Monkey)
Mar-14-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-13-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Mar-05-25 09:05AM	Clinical Data from Open-Label DAFFODIL Study Evaluating Long-term Safety of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Med (Business Wire)
06:36AM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised) (Zacks)
Mar-03-25 09:05AM	Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study (Business Wire) -7.35%
Feb-28-25 12:01PM	ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-27-25 04:05PM	Acadia Pharmaceuticals to Participate in the TD Cowens 45th Annual Health Care Conference (Business Wire)
12:01PM	ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
Feb-26-25 05:25PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Zacks)
04:35PM	Acadia: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Feb-14-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-13-25 08:30AM	Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock? (Zacks)
Feb-12-25 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (Business Wire)
Jan-17-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-14-25 01:10PM	Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025 (GuruFocus.com) -5.59%
09:05AM	Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
09:00AM	Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome (Business Wire)
Jan-12-25 09:33AM	Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-02-25 02:58AM	Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing (Insider Monkey)
Dec-30-24 05:37PM	Acadia Pharmaceuticals Set to Join SandP SmallCap 600 (PR Newswire) +9.95%
05:37PM	Acadia Pharmaceuticals Set to Join S&P SmallCap 600 (PR Newswire)
Dec-19-24 04:05PM	Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 (Business Wire)
Dec-16-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 04:05PM	Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million (Business Wire)
Dec-09-24 09:00AM	Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer (Business Wire) +8.56%
Dec-03-24 09:50AM	Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term (Zacks)
08:32AM	Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GAROFALO ELIZABETH A.	Director	Sep 02 '25	Sale	25.98	1,600	41,560	25,382	Sep 03 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 18 '25	Sale	25.18	22,000	554,024	40,130	Aug 19 06:00 PM
Schneyer Mark C.	Officer	Aug 18 '25	Proposed Sale	25.33	22,000	557,260		Aug 18 04:31 PM
Brege Laura	Director	Jun 04 '25	Sale	21.78	14,446	314,634	15,095	Jun 05 06:01 PM
LAURA BREGE	Director	Jun 04 '25	Proposed Sale	21.78	14,446	314,638		Jun 04 04:35 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 16 '25	Sale	22.50	4,000	90,000	20,395	May 19 08:52 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 16 '25	Sale	25.00	2,000	50,000	62,130	May 19 08:50 PM
Schneyer Mark C.	Officer	May 16 '25	Proposed Sale	17.60	2,000	35,200		May 16 05:10 PM
Kihara James	Officer	May 16 '25	Proposed Sale	17.60	4,000	70,400		May 16 05:06 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 02 '25	Sale	14.60	1,327	19,374	23,526	May 02 08:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 02 '25	Sale	14.60	3,498	51,071	62,773	May 02 07:59 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '25	Sale	14.82	2,708	40,133	59,456	Apr 08 07:40 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '25	Sale	14.82	1,028	15,235	22,257	Apr 08 07:38 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Mar 26 '25	Sale	17.05	1,095	18,670	21,275	Mar 26 08:10 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 26 '25	Sale	17.05	3,171	54,066	56,889	Mar 26 08:06 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Sale	18.23	4,919	89,673	17,595	Mar 06 06:30 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Proposed Sale	18.23	4,919	89,673		Mar 06 12:17 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 24 '25	Sale	19.96	475	9,481	20,228	Feb 25 06:48 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 24 '25	Sale	19.96	773	15,429	53,882	Feb 25 06:46 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Nov 19 '24	Sale	16.81	10,329	173,630	62,105	Nov 19 08:43 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Nov 19 '24	Sale	16.81	4,073	68,467	19,863	Nov 19 08:41 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Nov 19 '24	Sale	16.81	10,259	172,454	53,302	Nov 19 08:40 PM

PCRX Pacira BioSciences Inc daily Stock Chart

Peers: INCY EXEL ACAD RDUS ENTA CORT ANAB LGND AMLX PBYI

| Held by: IJR IWM VTI AVUV VB VBR IJS SPSM VXF IWN

Index	RUT	P/E	-	EPS (ttm)	-2.79	Insider Own	4.90%	Shs Outstand	44.90M	Perf Week	2.53%
Market Cap	1.22B	Forward P/E	8.31	EPS next Y	3.26	Insider Trans	-1.22%	Shs Float	42.73M	Perf Month	8.31%
Enterprise Value	1.40B	PEG	-	EPS next Q	0.65	Inst Own	115.94%	Short Float	15.46%	Perf Quarter	10.92%
Income	-127.46M	P/S	1.73	EPS this Y	-10.36%	Inst Trans	2.38%	Short Ratio	10.19	Perf Half Y	19.52%
Sales	705.85M	P/B	1.61	EPS next Y	13.73%	ROA	-8.01%	Short Interest	6.61M	Perf YTD	43.95%
Book/sh	16.88	P/C	2.73	EPS next 5Y	5.43%	ROE	-15.57%	52W High	27.64 -1.88%	Perf Year	104.68%
Cash/sh	9.92	P/FCF	10.41	EPS past 3/5Y	- -51.99%	ROIC	-10.83%	52W Low	12.61 115.07%	Perf 3Y	-49.71%
Dividend Est.	-	EV/EBITDA	9.14	Sales past 3/5Y	8.98% 10.73%	Gross Margin	70.08%	Volatility	4.00% 3.35%	Perf 5Y	-55.18%
Dividend TTM	-	EV/Sales	1.99	EPS Y/Y TTM	-301.59%	Oper. Margin	9.01%	ATR (14)	0.93	Perf 10Y	-52.41%
Dividend Ex-Date	-	Quick Ratio	1.91	Sales Y/Y TTM	2.25%	Profit Margin	-18.06%	RSI (14)	64.41	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	2.38	EPS Q/Q	-127.42%	SMA20	3.62%	Beta	0.42	Target Price	29.00
Payout	-	Debt/Eq	0.83	Sales Q/Q	1.73%	SMA50	11.88%	Rel Volume	0.93	Prev Close	27.03
Employees	790	LT Debt/Eq	0.55	Earnings	Aug 05 AMC	SMA200	14.27%	Avg Volume	648.30K	Price	27.12
IPO	Feb 03, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.23% -1.08%	Trades		Volume	601,835	Change	0.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Upgrade	Truist	Hold → Buy	$30
Jan-30-25	Upgrade	Truist	Sell → Hold	$8 → $25
Aug-13-24	Downgrade	Truist	Buy → Sell	$30 → $8
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$37 → $14
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $11
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight	$45 → $10
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight	$38 → $25
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75
Apr-21-21	Resumed	JP Morgan	Neutral	$70
Apr-09-21	Initiated	Berenberg	Buy	$93
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$86
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform	$72 → $75
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$75

Show Previous Ratings

Sep-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-25 06:04PM	Hanesbrands, Rogers, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-06-25 03:27AM	Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... (GuruFocus.com)
Aug-05-25 08:00PM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings (Zacks)
05:35PM	Pacira (PCRX) Tops Q2 Earnings Estimates (Zacks)
04:35PM	Loading…
04:35PM	Pacira: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:45AM	What To Expect From Pacira BioSciences Inc (PCRX) Q2 2025 Earnings (GuruFocus.com)
Jul-31-25 12:12PM	PharmaCorp Announces Filing of Annual Information Form (GlobeNewswire)
Jul-24-25 08:00AM	Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 (GlobeNewswire)
Jul-22-25 08:00AM	Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts (GlobeNewswire)
Jul-16-25 08:40AM	Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit (PR Newswire)
Jul-10-25 11:41AM	Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement (Insider Monkey)
Jul-03-25 04:01PM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-18-25 11:06AM	Is the Options Market Predicting a Spike in Pacira BioSciences Stock? (Zacks)
08:00AM	Loading…
08:00AM	Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient's Journey to Pain Relief and Innovation in Care at BIO 2025 (GlobeNewswire)
Jun-11-25 08:00AM	Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee (GlobeNewswire)
Jun-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 02:02PM	PharmaCorp Rx Inc. Reports First Quarter 2025 Results and Announces Non-Binding Letters of Intent to Acquire Four Pharmacies (GlobeNewswire)
May-15-25 08:00AM	Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee (GlobeNewswire)
May-14-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
May-13-25 10:35AM	Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation (PR Newswire) -6.74%
May-09-25 11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
03:41AM	Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... (GuruFocus.com)
May-08-25 05:30PM	Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Pacira (PCRX) Q1 Earnings Surpass Estimates (Zacks)
04:11PM	Pacira: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 05:20PM	Pacira BioSciences Q1 2025 Earnings Preview (Seeking Alpha)
10:20AM	Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
06:05PM	Loading…
May-06-25 06:05PM	Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
May-02-25 08:00AM	Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis (GlobeNewswire)
May-01-25 05:10PM	Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates (Zacks)
10:01AM	ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:34AM	IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
08:32AM	Pharmacorp Completes Acquisition of Pre-1954 Charter Company in Ontario (GlobeNewswire)
Apr-29-25 10:01AM	Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:00AM	Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 (GlobeNewswire)
Apr-28-25 08:00AM	Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire) +5.52%
Apr-22-25 04:01PM	Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire)
Apr-21-25 12:10PM	Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again (Zacks) +5.07%
08:15AM	DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders (PR Newswire)
Apr-17-25 05:00PM	Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders (GlobeNewswire)
Apr-15-25 01:45PM	Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
Apr-11-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-10-25 05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks) -8.32%
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks)
10:03AM	Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act (Seeking Alpha)
09:41AM	Pacira price target raised to $28 from $25 at Truist (TipRanks)
05:53AM	Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains? (Zacks)
Apr-08-25 11:29AM	PCRX Stock Soars on Exparel Patent Settlement With Generic Players (Zacks) +14.67%
Apr-07-25 04:30PM	Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks)
09:37AM	PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study (Zacks)
Apr-03-25 08:00AM	Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 12:39PM	Pacira Surges 66.8% in Six Months: How Should You Play the Stock? (Zacks)
Mar-14-25 04:05PM	Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual (GlobeNewswire)
08:25AM	DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences (PR Newswire)
Mar-06-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-25 07:00AM	Bull of the Day: Pacira BioSciences (PCRX) (Zacks)
Mar-02-25 12:27PM	Is Pacira BioSciences, Inc. (PCRX) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-28-25 10:09AM	Q4 2024 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.24%
02:36AM	Pacira BioSciences Inc (PCRX) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Feb-27-25 05:26PM	Pacira: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
04:00PM	Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio (GlobeNewswire)
Feb-26-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March (GlobeNewswire)
07:46AM	What To Expect From Pacira BioSciences Inc (PCRX) Q4 2024 Earnings (GuruFocus.com)
Feb-20-25 09:50AM	Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term (Zacks)
08:00AM	Pacira to Report 2024 Financial Results on Thursday February 27, 2025 (GlobeNewswire)
Feb-14-25 05:45AM	Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX (PR Newswire)
Feb-06-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 09:55AM	Should You Buy Pacira (PCRX) After Golden Cross? (Zacks)
Jan-31-25 05:45AM	Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX (PR Newswire)
Jan-30-25 08:00AM	Pacira Announces Updates to Board of Directors (GlobeNewswire)
Jan-21-25 08:00AM	Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments (GlobeNewswire)
Jan-16-25 01:56PM	Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights PCRX (GlobeNewswire)
Jan-10-25 08:00AM	Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization (GlobeNewswire) +11.09%
Jan-07-25 11:49AM	Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain (Benzinga)
08:00AM	Pacira BioSciences Receives FDA 510k Clearance for New iovera SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block (GlobeNewswire)
Jan-02-25 04:01PM	Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 09:50AM	Here's Why Pacira (PCRX) is a Strong Momentum Stock (Zacks)
Dec-11-24 08:05AM	DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc. (PR Newswire)
Dec-06-24 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Dec-03-24 07:30AM	Pacira Awarded New U.S. Patent Covering EXPAREL Composition (GlobeNewswire) -6.34%
Nov-29-24 09:50AM	Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-14-24 10:05AM	Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee (GlobeNewswire)
Nov-12-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
Nov-07-24 08:49AM	Q3 2024 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
02:20AM	Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Nov-06-24 04:10PM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 07:55AM	Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.05%
Nov-04-24 08:00AM	Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings (GlobeNewswire)
Oct-30-24 08:00AM	Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 (GlobeNewswire)

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ceesay Abraham	Director	Sep 04 '25	Sale	27.19	2,354	64,005	9,039	Sep 08 05:37 PM
Ceesay Abraham	Director	Sep 04 '25	Proposed Sale	27.19	2,354	64,005		Sep 04 09:40 AM
BIGAL MARCELO	Director	Aug 07 '25	Sale	23.67	4,912	116,267	11,393	Aug 11 04:09 PM
BIGAL MARCELO	Director	Aug 07 '25	Proposed Sale	23.67	4,912	116,279		Aug 07 03:17 PM
RIKER LAUREN	Senior Vice President, Finance	Jun 04 '25	Sale	26.21	5,578	146,208	59,564	Jun 05 05:40 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 04 '25	Sale	26.24	14,376	377,226	161,574	Jun 05 05:37 PM
RIKER LAUREN	Officer	Jun 04 '25	Proposed Sale	26.21	5,579	146,209		Jun 04 11:36 AM
WILLIAMS KRISTEN	Officer	Jun 04 '25	Proposed Sale	26.24	14,376	377,226		Jun 04 10:37 AM
GAUGLER DARYL	Officer	Mar 06 '25	Proposed Sale	23.25	500	11,625		Mar 06 12:06 PM
SLONIN JONATHAN	Chief Medical Officer	Jan 06 '25	Sale	18.40	879	16,174	93,444	Jan 06 06:23 PM
SLONIN JONATHAN	Officer	Jan 06 '25	Proposed Sale	18.40	879	16,174		Jan 06 11:11 AM
GAUGLER DARYL	Chief Operating Officer	Dec 13 '24	Sale	19.76	500	9,880	115,200	Dec 16 04:13 PM
GAUGLER DARYL	Officer	Dec 13 '24	Proposed Sale	19.76	500	9,880		Dec 13 09:41 AM

MIRM

Mirum Pharmaceuticals Inc

ACAD

Acadia Pharmaceuticals Inc

PCRX

Pacira BioSciences Inc

Upgrade your FINVIZ experience